Latest Genzyme Stories

EXTON, Penn., Jan. 16, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the recent commercial availability of Genzyme's Aubagio, the second oral disease-modifying agent (DMA) to the market following Novartis's launch of Gilenya in late 2010, is top of mind for few neurologists as a change in the management or treatment of their multiple sclerosis (MS) patients. Instead, data from...

EXTON, Pa., Jan. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that 16 percent of surveyed U.S. neurologists have initiated a trial of Genzyme's Aubagio, the second oral disease-modifying agent (DMA) to the multiple sclerosis (MS) market at one month post-launch, capturing less than one percent share among DMA-treated relapsing remitting MS patients. With Aubagio's oral...

BRIDGEWATER, N.J., Jan. 8, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that David Meeker, M.D., President and Chief Executive Officer of Genzyme, a Sanofi Company, has been elected to Savient's Board of Directors, effective January 7, 2013. In addition, Savient announced the resignation from the Company's Board of William F. Owen, Jr., M.D., who is relocating to Qatar to serve as Chief Executive Officer of the Sidra Medical and Research Center, a...

CARLSBAD, Calif., Dec. 14, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will review the CHMP opinion on KYNAMRO(TM) in a conference call and webcast on Friday, December 14, 2012 at 8:30 a.m. Eastern Time. This call will be archived for a limited time on Isis' Web site. CONFERENCE CALL At 8:30 a.m. Eastern Time, Friday, December 14, 2012, Isis will conduct a live webcast and conference call. Interested parties may listen to the call by...

BRIDGEWATER, N.J., Dec. 12, 2012 /PRNewswire/ -- Sanofi US announced today that Registries for All Diseases has been selected as the winner of the Collaborate Activate Innovation Challenge. Registries for All Diseases will receive an award of $300,000 to create a comprehensive, crowdsourced, cross-disease registry to help accelerate translational research for over 1,000 diseases. The team consists of partnering organizations Genetic Alliance, CFIDS Association of America, National...

CARLSBAD, Calif., Nov. 6, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $26.0 million and $36.0 million for the three and nine months ended September 30, 2012, respectively, compared to a pro forma NOL of $20.0 million and $44.9 million for the same periods in 2011. The Company ended the third quarter of 2012 with $343.6 million in cash. "We have had a very successful year. With a number of exciting events on...

SOUTH PLAINFIELD, N.J., Nov. 6, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Geoffrey McDonough, M.D., to the company's Board of Directors. Dr. McDonough is the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a leading European specialty pharmaceutical company developing therapies for patients with rare disorders and significant medical needs. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) "We are...

Lawrence LeBlond for redOrbit.com - Your Universe Online A new drug to fight multiple sclerosis (MS) is showing promise as one of the “most effective” treatment options ever produced for the debilitating disease, according to UK researchers. The drug, which is used to ‘reboot’ a person’s immune system, has been shown to be effective in MS patients who have already failed to respond to the first drug with which they were treated, as well as those who have gone previously...

SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s)...

PARIS, Oct. 25, 2012 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2012 Change on a reported Change at 9-month 2012 Change on a reported basis basis Change at constant constant exchange rates(1)...